A multilaboratory study designed to determine the in vitro susceptibility criteria and quality control parameters for ofloxacin against Neisseria gonorrhoeae was conducted according to the guidelines of the National Committee for Clinical Laboratory Standards. Proposed susceptibility breakpoints are MICs of <0.25 ,ug/ml for the agar dilution test and .31 mm for the disk diffusion test. A category for resistance could not be defined. Proposed acceptable quality control MICs for N. gonorrhoeae ATCC 49226 and Staphylococcus aureus ATCC 29213 range from 0.004 to 0.03 ,ug/ml and 0.25 to 1.0 ,ug/ml, respectively. With 5-,ug ofloxacin disks, acceptable inhibitory zone diameters for S. aureus ATCC 25923 and the N. gonorrhoeae control strains range from 22 to 27 mm and 43 to 51 mm, respectively.
Ofloxacin is a fluoroquinolone with broad-spectrum antibacterial activity that has recently been released for clinical use in the United States. Several studies have demonstrated the efficacy of ofloxacin in the treatment of uncomplicated gonococcal infections, including those caused by ,B-lactamase-producing strains (2, 3, (5) (6) (7) . The potential usefulness of ofloxacin for the treatment of urethritis or cervicitis is enhanced by its reported effectiveness in treating these infections when they are caused by Chlamydia trachomatis and Ureaplasma urealyticum (1, 5) .
Interpretive criteria and quality control parameters for the susceptibility testing of nonfastidious bacteria to ofloxacin by broth dilution and disk diffusion methods have been established (8, 9) . For fastidious organisms, such as Neisseria gonorrhoeae, these parameters have not been determined. This report presents results of a multilaboratory study designed in accordance with the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) (10) to develop (i) interpretive criteria for ofloxacin susceptibility testing of N. gonorrhoeae and (ii) quality control parameters for both methods of testing.
Ofloxacin susceptibility testing was performed in accordance with the methods outlined by NCCLS (8, 9) ,ug/ml, and all but one isolate was susceptible to ofloxacin at a concentration of <0.125 ,ug/ml. In published clinical studies (2, 3, 5, 6), 100% of uncomplicated genital gonococcal infections were cured by ofloxacin therapy, and for all of the causative organisms tested, ofloxacin MICs were <0.125 ,ug/ml. On the basis of the available clinical data, the isolates in the current study would be considered susceptible to ofloxacin. To obtain isolates for which the MICs were higher, relatively resistant strains were developed by repeated in vitro exposure of the strains to increasing concentrations of ofloxacin and other fluoroquinolones. This in vitro selection process provided 21 strains for which the ofloxacin MICs were 0.5 to >4.0 ,ug/ml; they are included in Fig. 1 as those strains for which the MICs were .0.5 ,ug/ml. The ofloxacin inhibitory zone diameters for the 102 susceptible isolates were >31 mm in all instances, but for the 21 strains with induced resistance, the inhibitory zone diameters were <30 mm. We propose, therefore, that N. gonorrhoeae be considered susceptible to ofloxacin when the ofloxacin MIC is .0.25 pg/ml or the inhibitory zone diameter around a 5-,ug ofloxacin disk is 231 mm. Ofloxacinresistant clinical isolates of N. gonorrhoeae have yet to be described, and criteria for ofloxacin resistance should await clinical data on treatment failures and correlations with MICs. Isolates for which the confirmed MICs are >0.25 ,ug/ml or zone diameters are <31 mm are not necessarily resistant clinically, but they are relatively resistant in comparison with those isolates that have been studied to date.
For the development of quality control parameters, tests were conducted in the laboratories directed by each of the five authors, in accordance with the recommendations of NCCLS (10) . Antibiotic powders of certified potency were supplied to each facility, together with supplement and two lots of GC agar (one lot was common to all facilities and the other lot was unique to each facility). The six lots were obtained from the following three manufacturers: BectonDickinson Microbiology Systems (three lots), Difco Laboratories (two lots), and Oxoid Laboratories (one lot). 
